ArticleFASEB bioAdvances2022
Maternal
Article in FASEB bioAdvances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- miR-9394b from Lactobacillus paracasei extracellular vesicles targets iNOS to reprogram host NO-ornithine metabolism and ameliorate DSS-induced murine colitis.NPJ biofilms and microbiomes · 2026Article
- Decoding NEC: epigenetic biomarkers for risk stratification and prognosis.Pediatric research · 2026Article
- Human milk and infant formula influence lactobacilli metabolism in a species-specific manner.NPJ science of food · 2026Article
- Early life factors, diet and microbiome, and risk of inflammatory bowel disease.Journal of the Canadian Association of Gastroenterology · 2025Article
- The treatment naïve microbiome of pediatric ulcerative colitis and microbial therapeutics: A humbling challenge.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Evaluating the Therapeutic Efficacy ofCurrent pharmaceutical design · 2025Review
- Intestinal dysbiosis during pregnancy and microbiota-associated impairments in offspring.Frontiers in microbiomes · 2025Review
- INVITED COMMENTARY on Andersen S, et al. Developmental Windows of Environmental Vulnerability for Inflammatory Bowel Disease.Journal of pediatrics. Clinical practice · 2024Article
- Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022.Frontiers in microbiology · 2023Review
- Maternal Intake of Probiotics to Program Offspring Health.Current nutrition reports · 2022Review
- MaternalFASEB bioAdvances · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
The purpose of our experiment was to explore how stochastic (inter-individual variation) gut microbiome composition may link to inflammatory bowel disease (IBD) susceptibility and guide the development of a perinatal preventative probiotic. Dextran sodium sulfate (DSS) was introduced to C57BL/BJ mice to induce acute colitis as a model of IBD. Potentially protective bacteria were identified using a discovery-validation cohort approach toward stochastic DSS susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.